We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Debiopharm Group and Mercury Therapeutics Sign Development and Commercialization of Debio 0930
News

Debiopharm Group and Mercury Therapeutics Sign Development and Commercialization of Debio 0930

Debiopharm Group and Mercury Therapeutics Sign Development and Commercialization of Debio 0930
News

Debiopharm Group and Mercury Therapeutics Sign Development and Commercialization of Debio 0930

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Debiopharm Group and Mercury Therapeutics Sign Development and Commercialization of Debio 0930"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Debiopharm Group (Debiopharm) and Mercury Therapeutics, Inc. (Mercury) have announce the signature of an exclusive license agreement for the development and commercialization of Debio 0930, a small molecule activator of AMPK (adenosine monophosphate activated protein kinase) for the treatment of diabetes and metabolic diseases.

Activation of AMPK has been shown to lower fasting blood glucose levels and improve glucose disposal following a glucose challenge, two key goals in the management of type 2 diabetes.

Under the terms of the agreement, Debiopharm shall pay Mercury for continued research and development support, predefined advanced milestone payments during the development of the compound and a royalty based on net sales of commercialized product. First entry into man is expected for 2012.

“We are very enthusiastic about our collaboration with an experienced innovative biotech company like Mercury. Diabetes is a major cause of morbidity and mortality by disease globally and we are determined to improve the quality of patient’s lives by developing a new therapy,” said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group.”

“This alliance with Debiopharm represents important validation of Mercury’s technology and of the growing appreciation of AMPK as a novel drug target for metabolic diseases. The development of an orally available direct activator of AMPK has the potential to be a first-in-class therapeutic for type 2 diabetes, hyperlipidemia, and a number of indications in oncology,” added Dr. Neal Birnberg, CEO of Mercury, who was advised on this transaction by Katan Associates.
Advertisement